Abstract
Antisense compounds, various forms of nucleotides or their analogs, inhibit gene function both in vitro and in vivo. Although antisense compounds have been used extensively not only as a basic research tool but also as therapeutics for various diseases, one of the major problems is the difficulty of obtaining optimal sequences to inhibit specific gene functions. Although the terms “sequence-specificity” or “sequence-nonspecificity” are often used, there is no consensus as to how to define and quantitate such sequence specificity. In this review, we introduced hybridization simulation for designing optimal antisense sequences. Each candidate antisense oligonucleotide is assessed by calculating its hybridization energy against potential hybridization sites within the specified database (including Genbank) using a realistic nearest-neighbor thermodynamic model, taking into account mismatches. The specificity of each oligonucleotide is then quantitated by the number of potential cross-hybridizable genes and their degree of cross-hybridization. Further-more, if antisense sequences exhibit a high potential for hairpin formation, they are not recommended even if they are highly specific. Therefore, to select antisense sequences, one should calculate all the potential factors for each candidate oligonucleotide such as length, location, specificity, hairpin potential, mRNA secondary structure, and dimer formation.
Similar content being viewed by others
References
Zon G. Brief overview of control of genetic expression by antisense oligonucleotides and in vivo applications. Prospects for neurobiology. Mol Neurobiol 1995;10:219–229.
Crooke ST. Progress in antisense therapeutics. Hematol Pathol 1995;9:59–72.
Brysch W, Schlingensiepen KH. Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents. Cell Mol Neurobiol 1994;14:557–568.
Narayanan R. Antisense therapy of cancer. In Vivo 1994;8:787–793.
Agrawal S, Temsamani J, Galbraith W, et al. Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet 1995;28:7–16.
Stein CA, Cheng Y-C. Antisense oligonucleotides as therapeutic agents. Is the bullet really magical? Science 1993;261:1004–1012.
Zhang R, Yan J, Shahinian H, et al. Pharmacokinetics of an antihuman immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin Pharmacol Ther 1995;58:44–53.
Wagner RW. Gene inhibition using antisense oligodeoxynucleotides. Nature 1994;372:333–335.
Egholm M, Buchardt O, Nielsen P, et al. Peptide nucleic acids (PNA). Oligonucleotide analogues with an achiral peptide backbone. J Am Chem Soc 1992;114:1895–1897.
Stirchak E, Summerton J, Weller D. Uncharged stereoregular nucleic acid analogs: 2. Morpholino nucleoside oligomers with carbamate internucleoside linkages. Nucleic Acids Res 1989;17: 6129–6141.
Stein C, Cohen J. Phosphorothioate oligonucleotide analog. In: Cohen J (ed) Oligonucleotides: Antisense inhibitors of gene expression. Boca Raton: CRC, 1989:97–117.
Mitsuhashi M, Cooper A, Ogura M, et al. Oligonucleotide probe design—a new approach. Nature 1994;367:759–761.
Hyndman D, Cooper A, Pruzinsky S, et al. Software to determine optimal oligonucleotide sequences based on thermodynamic hybridizability. Biotechniques 1996;20:1090–1097.
Breslauer KJ, Frank R, Blocker H, et al. Predicting DNA duplex stability from the base sequence. Proc Natl Acad Sci USA 1986;83:3746–3750.
SantaLucia J, Allawi HT, Seneviratne PA. Improved nearest-neighbor parameters for predicting DNA duplex stability. Biochemistry 1996;35:3555–3562.
SantaLucia J, Kierzek R, Turner DH. Effects of GA mismatches on the structure and thermodynamics of RNA internal loops. Biochemistry 1990;29:8813–8819.
Sugimoto N, Kierzek R, Freier SM, et al. Energetics of internal GC mismatches in ribooligonucleotide helix. Biochemistry 1986; 25:5755–5759.
Fakler B, Herlitzer S, Amthor B, et al. Short antisense oligonucleotide-mediated inhibition is strongly dependent on oligo length and concentration but almost independent of location of the target sequence. J Biol Chem 1994;269:16187–16194.
Spearman M, Taylor WR, Greenberg AH, et al. Antisense oligodeoxyribonucleotide inhibition of TGF-beta 1 gene expression and alterations in the growth and malignant properties of mouse fibrosarcoma cells. Gene 1994;149:25–29.
Moria BP, Johnston JF, Ecker DJ, et al. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J Biol Chem 1992;267:19954–19962.
Bennett CF, Condon TP, Grimm S, et al. Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. J Immunol 1994;152:3530–3540.
Hodges D, Crooke ST. Inhibition of splicing of wild-type and mutated luciferase-adenovirus pre-mRNAs by antisense oligonucleotides. Mol Pharmacol 1995;48:905–918.
Giles RV, Spiller DG, Green JA, et al. Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNA. Blood 1995;86:744–754.
Pari GS, Field AK, Smith JA. Potent antiviral activity of an antisense oligonucleotide complementary to the intron-exon boundary of human cytomegalovirus genes UL36 and UL37. Antimicrob Agents Chemother 1995;39:1157–1161.
Wilbur WJ, Lipman DJ. Rapid similarity searches of nucleic acid and protein data banks. Proc Natl Acad Sci USA 1983;80:726–730.
Pearson WR, Lipman DJ. Improved tools for biological sequence analysis. Proc Natl Acad Sci USA 1988;85:2444–2448.
Smith TF, Waterman MS. Comparison of bio-sequences. Adv Appl Math 1981;2:482–489.
Turner DH, Sugimoto N, Freier SM. RNA structure prediction. Ann Rev Biophys Chem 1988;17:167–192.
Sugimoto N, Nakano S, Katho M, et al. Thermodynamic parameters to predict stability of RNA/DNA hybrid duplexes. Biochemistry 1995;34:11211–11216.
Mitsuhashi M. Method of determining optimal PCR primers. Protein Nucleic Acid Enzyme 1996;41:439–445.
Jaeger JA, Turner DH, Zuker M. Improved predictions of secondary structures for RNA. Proc Natl Acad Sci USA 1989;86: 7706–7710.
Marschall P, Thomson JB, Eckstein F. Inhibition of gene expression with ribozymes. Cell Mol Neurobiol 1994;14:523–538.
Dean NM, McKay R. Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 1994; 91:11762–11766.
Wollnik F, Brysch W, Uhlmann E, et al. Block of c-Fos and JunB expression by antisense oligonucleotides inhibits light-induced phase shifts of the mammalian circadian clock. Eur J Neurosci 1995;7:388–393.
Burch RM, Mahan LC. Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice. J Clin Invest 1991;88:1190–1196.
Ensoli B, Markham P, Kao V, et al. Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS. J Clin Invest 1994;94:1736–1746.
Raffa RB, Martinez RP, Connelly CD. G-protein antisense oligodeoxyribonucleotides and mu-opioid supraspinal antinociception. Eur J Pharmacol 1994;258:R5–7.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mitsuhashi, M. Strategy for designing specific antisense oligonucleotide sequences. J Gastroenterol 32, 282–287 (1997). https://doi.org/10.1007/BF02936384
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02936384